A new trading day began on Friday, with Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) stock price up 3.04% from the previous day of trading, before settling in for the closing price of $43.47. CRNX’s price has ranged from $15.76 to $53.70 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 64.83%. Meanwhile, its annual earnings per share averaged 3.77%. With a float of $73.56 million, this company’s outstanding shares have now reached $78.86 million.
Let’s determine the extent of company efficiency that accounts for 290 employees.
Crinetics Pharmaceuticals Inc (CRNX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Crinetics Pharmaceuticals Inc is 6.72%, while institutional ownership is 98.54%. The most recent insider transaction that took place on Jun 26 ’24, was worth 42,427. In this transaction Chief Operating Officer of this company sold 956 shares at a rate of $44.38, taking the stock ownership to the 52,580 shares. Before that another transaction happened on Jun 25 ’24, when Company’s Chief Scientific Officer sold 3,000 for $45.37, making the entire transaction worth $136,110. This insider now owns 80,643 shares in total.
Crinetics Pharmaceuticals Inc (CRNX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 3.77% per share during the next fiscal year.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Trading Performance Indicators
Here are Crinetics Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 17.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.77, a number that is poised to hit -0.86 in the next quarter and is forecasted to reach -3.82 in one year’s time.
Technical Analysis of Crinetics Pharmaceuticals Inc (CRNX)
Looking closely at Crinetics Pharmaceuticals Inc (NASDAQ: CRNX), its last 5-days average volume was 1.74 million, which is a jump from its year-to-date volume of 0.85 million. As of the previous 9 days, the stock’s Stochastic %D was 42.84%. Additionally, its Average True Range was 2.00.
During the past 100 days, Crinetics Pharmaceuticals Inc’s (CRNX) raw stochastic average was set at 50.25%, which indicates a significant decrease from 52.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.91% in the past 14 days, which was lower than the 56.20% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $46.24, while its 200-day Moving Average is $38.03. However, in the short run, Crinetics Pharmaceuticals Inc’s stock first resistance to watch stands at $45.48. Second resistance stands at $46.16. The third major resistance level sits at $47.35. If the price goes on to break the first support level at $43.61, it is likely to go to the next support level at $42.42. Now, if the price goes above the second support level, the third support stands at $41.74.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Key Stats
With a market capitalization of 3.53 billion, the company has a total of 78,860K Shares Outstanding. Currently, annual sales are 4,010 K while annual income is -214,530 K. The company’s previous quarter sales were 640 K while its latest quarter income was -66,930 K.
